Alnylam Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Hoffmann-la Roche Inc.

The Scripps Research Institute

Arrowhead Research Corporation

F. Hoffmann-la Roche Ag

Birgit Bramlage

Pamela Tan

Hans-Peter Vornlocher

Kevin Fitzgerald

Akin Akinc

Maria Frank-Kamenetsky

Victor E Kotelianski

David A Bumcrot

Philipp Hadwiger

Dinah Wen-Yee Sah

Ingo Roehl

Dinah Sah

Markus Hossbach

John Frederick Boylan

John Reidhaar-Olson

Rainer Constien

William Balch

Antonin De Fougerolles

Guy Georges

Ulrich Brinkmann

Olaf Mundigl

Werner Scheuer

Eike Hoffmann

Alexander Haas

Matthias John

Rebecca Croasdale

Kerstin Jahn-Hofmann

Jan Olaf Stracke

Ludger Ickenstein

Silke Metz

Michael Grote

Wilma Dormeyer

Simone Dill

John Benson

Ludger Markus Ickenstein

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.

Compositions and methods for inhibiting expression of RRM2 genes

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.

Compositions and methods for inhibiting expression of the PCSK9 gene

This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Bi-specific digoxigenin binding antibodies

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.

Compositions and methods for inhibiting expression of a gene from the JC virus

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.

Compositions and methods for inhibiting expression of huntingtin gene

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition.

Compositions and methods for inhibiting expression of the MYC gene

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.

RNAi modulation of Aha and therapeutic uses thereof

Compositions and methods for inhibiting expression of Huntingtin gene

Growing community of inventors

Kulmbach, Germany

Birgit Bramlage